Current preclinical or clinical therapies targeting TGF‐β include antisense molecules, anti‐TGF‐β cancer vaccines, monoclonal antibodies against TGF‐β, latent TGF‐β targeted therapy, Soluble TGF‐βRII and soluble TGF‐βRIII (betaglycan), TGF‐β receptor kinase inhibitors (TRKI).184. Here, TGFB1 is linked to cancer.